Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Westmead Hospital, Westmead, NSW 2145, Australia; Department of Gastroenterology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China.
Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Westmead Hospital, Westmead, NSW 2145, Australia.
Cancer Lett. 2017 Apr 1;390:188-200. doi: 10.1016/j.canlet.2016.12.037. Epub 2017 Jan 13.
Chimeric antigen receptors (CARs) are a series of manufactured receptors that have the capacity of binding to specific antigens expressed on surface of tumor cells. A CAR normally has an extracellular antigen recognition domain derived from single variable chain of a monoclonal antibody, a transmembrane domain and an intracellular T cell activation domain. During the last decade, CAR-T cells were demonstrated to possess great therapeutic effects on hematological malignancies. However, strategies using CAR-T cells to treat solid tumors have been hindered by considerable obstacles including "on tissue off target" effects and cytokine storm syndrome. This review will summarize the current understanding of CAR-T cell therapies and briefly describe the currently enrolled clinical trials in solid tumors.
嵌合抗原受体 (CARs) 是一系列经过人工改造的受体，具有与肿瘤细胞表面表达的特定抗原结合的能力。CAR 通常具有一个来源于单克隆抗体的单可变链的细胞外抗原识别结构域、一个跨膜结构域和一个细胞内 T 细胞激活结构域。在过去的十年中，CAR-T 细胞已被证明对血液系统恶性肿瘤具有很好的治疗效果。然而，利用 CAR-T 细胞治疗实体瘤的策略受到了相当多的障碍的阻碍，包括“组织外靶”效应和细胞因子风暴综合征。本综述将总结 CAR-T 细胞治疗的现有认识，并简要描述目前正在进行的实体瘤临床试验。
